Stockscreener 앱 받기
21.70
1.59%
-0.35
전일 마감가:
$22.05
열려 있는:
$22.05
하루 거래량:
1.96M
Relative Volume:
0.71
시가총액:
$2.75B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-10.69
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
-7.62%
1개월 성능:
+1.73%
6개월 성능:
-18.36%
1년 성능:
-20.98%
1일 변동 폭
$21.54
$22.55
1주일 범위
$21.54
$23.69
52주 변동 폭
$16.10
$30.48
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
21.70 | 2.79B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2026-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Apellis Pharma chief business officer sells $8k in stock By Investing.com - Investing.com Canada
What are the risks of holding Apellis Pharmaceuticals Inc.Weekly Trend Recap & Precise Entry and Exit Recommendations - mfd.ru
(APLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Apellis Pharmaceuticals (APLS) Valuation Check After Recent S&P 1000 Index Inclusion - Yahoo Finance
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC - MarketBeat
ING Groep NV Acquires 866,200 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Market Overview: Will Apellis Pharmaceuticals Inc outperform the market in YEARWeekly Trade Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS) - simplywall.st
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions - Sahm
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors - Sahm
(APLS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential - Finviz
Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsShort Setup & Reliable Intraday Trade Alerts - mfd.ru
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded to Hold at Barclays - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
J. Safra Sarasin Holding AG Sells 45,184 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 7.5%Still a Buy? - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Equal-Weight Rating from Barclays | APLS Stock News - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Barclays - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 56.89% Upside Potential - DirectorsTalk Interviews
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
A Look At Apellis Pharmaceuticals (APLS) Valuation As GAAP Profitability And Syfovre Commercialization Gain Traction - Yahoo Finance
Apellis Turns GAAP Profitable As Syfovre Sales Shift Story To Execution - Sahm
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by EFG Asset Management North America Corp. - MarketBeat
Value Recap: Is BAFN a strong growth stockGap Up & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Buybacks Report: Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Apellis upgraded at BofA on launch trajectory for kidney disease therapy - MSN
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Apellis Pharma CEO Francois sells $592k in shares By Investing.com - Investing.com Canada
Caroline Baumal Sells 2,797 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David Watson Sells 7,832 Shares - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells 2,064 Shares of Stock - MarketBeat
Timothy Eugene Sullivan Sells 10,287 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis stock surges after Sobi $300 million royalty deal - MSN
Aug Retail: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialSell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy - ChartMill
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock - Investing.com Nigeria
Apellis Pharma CMO Baumal sells $37k in shares By Investing.com - Investing.com India
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock By Investing.com - Investing.com South Africa
Apellis Pharma VP Chopas sells $14k in shares By Investing.com - Investing.com Canada
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells 8,182 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 909 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 2,475 Shares of Stock - MarketBeat
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):